Scholarlink

Background <p>We previously demonstrated that immune cells expressing α-synuclein (SNCA) are dramatically increased in peripheral blood of patients with gastric cancer (GC), but rarely in healthy donors, and that blocking SNCA is significantly effective even in anti-PD1-resistant mouse tumor models with increased SNCA<sup>+</sup> cells. This suggests that the increased SNCA<sup>+</sup> cells are involved in resistance to anti-PD1 therapy. However, the relationship between SNCA<sup>+</sup> cell levels and anti-PD1/PDL1 therapeutic efficacy in GC remains to be determined in clinical settings.</p> Methods <p>In the WJOG10417GTR study, peripheral blood cells collected from advanced GC patients before and one month after nivolumab monotherapy were analyzed for several SNCA<sup>+</sup> cell populations by flow cytometry, and the relationship between the levels and patient prognosis was statistically analyzed.</p> Results <p>High levels of SNCA<sup>+</sup> cells, particularly the myeloid subset, before and after treatment were significantly associated with shorter progression-free survival and overall survival. Patients with low SNCA<sup>+</sup> cell levels survived for a long time without disease progression, indicating durable responders.</p> Conclusion <p>These suggest that SNCA<sup>+</sup> cells are significant poor prognostic factors in nivolumab therapy for advanced GC. Targeting SNCA may be a promising strategy to improve clinical outcomes in anti-PD1/PDL1 therapy for GC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Peripheral SNCA+ cells as a poor prognostic factor for nivolumab therapy in advanced gastric cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月22日

查看全文
  • Chie Kudo-Saito,
  • Hiroshi Imazeki,
  • Kengo Nagashima,
  • Hirokazu Shoji,
  • Kai Tsugaru,
  • Naoki Takahashi,
  • Takeshi Kawakami,
  • Yusuke Amanuma,
  • Takeru Wakatsuki,
  • Naohiro Okano,
  • Yukiya Narita,
  • Yoshiyuki Yamamoto,
  • Rika Kizawa,
  • Kei Muro,
  • Narikazu Boku

摘要

Background

We previously demonstrated that immune cells expressing α-synuclein (SNCA) are dramatically increased in peripheral blood of patients with gastric cancer (GC), but rarely in healthy donors, and that blocking SNCA is significantly effective even in anti-PD1-resistant mouse tumor models with increased SNCA+ cells. This suggests that the increased SNCA+ cells are involved in resistance to anti-PD1 therapy. However, the relationship between SNCA+ cell levels and anti-PD1/PDL1 therapeutic efficacy in GC remains to be determined in clinical settings.

Methods

In the WJOG10417GTR study, peripheral blood cells collected from advanced GC patients before and one month after nivolumab monotherapy were analyzed for several SNCA+ cell populations by flow cytometry, and the relationship between the levels and patient prognosis was statistically analyzed.

Results

High levels of SNCA+ cells, particularly the myeloid subset, before and after treatment were significantly associated with shorter progression-free survival and overall survival. Patients with low SNCA+ cell levels survived for a long time without disease progression, indicating durable responders.

Conclusion

These suggest that SNCA+ cells are significant poor prognostic factors in nivolumab therapy for advanced GC. Targeting SNCA may be a promising strategy to improve clinical outcomes in anti-PD1/PDL1 therapy for GC.